COMPLIANCE MONITORING IN PATIENTS WITH FATTY HEPATOSIS AT A RURAL THERAPEUTIC SITE
The aim of the research. To monitor compliance in patients with fatty hepatosis of various etiologies. Materials and methods. 1152 people out of 1568 residents of the rural therapeutic site agreed to participate in the study. The survey included: subjective data, including alcohol history, physical examination. The biochemical parameters of blood were studied: alanine aminotransferase, aspartate aminotransferase, total protein, albumin, prothrombin index. An ultrasound examination of the abdominal organs was performed. Adherence to therapy was assessed 6 months after treatment and lifestyle counseling. Results. Fatty hepatosis within the framework of alcoholic liver disease (ALD) was in 167 (14.5%) people, within the framework of non-alcoholic fatty liver disease (NAFLD) - in 225 (19.5%) (p>0.05). There were 43 smokers among patients with liver steatosis with NAFLD (19.1%), while those with ALD - 145 people (86.8%) (p  0.05). Of 124 patients with alcoholic fatty hepatosis at the age of 18-59 years, 11 (8.9%) people followed the recommendations, out of 43 patients 60 years and older - none (p> 0.05), while of 108 patients with non-alcoholic steatosis - 29 (26.9%) and 16 (13.7%) (p  0.05). Among patients with non-alcoholic hepatosis, compliance was more pronounced in people of working age (p <0.05). Among patients with liver steatosis with ALD, there were 86.8% smokers, with NAFLD - 19.1% (p <0.001). Smoking is an additional risk factor for the development of ALD. At the first contact with a doctor, only 13% of patients with alcoholic fatty hepatosis admit to alcohol abuse.